Latest "GeneChem Management Inc." News Stories

07:26 EST 17th November 2019 | BioPortfolio

Here are the most relevant search results for "GeneChem Management Inc." found in our extensive news archives from over 250 global news sources.

More Information about GeneChem Management Inc. on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about GeneChem Management Inc. for you to read. Along with our medical data and news we also list GeneChem Management Inc. Clinical Trials, which are updated daily. BioPortfolio also has a large database of GeneChem Management Inc. Companies for you to search.

Showing "GeneChem Management" News Articles 1–25 of 7,500+

Saturday 16th November 2019

Strategic & Technical Intelligence: A Prerequisite For Life Science Success

Given the dynamic nature of the life sciences industry coupled with its high financial stakes, it is prudent for a pharmaceutical company to expand its market intelligence program beyond the short-term needs of management and brand teams. By Bill Kelly, president and cofounder, BioInformatics LLC

10 Tips For Avoiding CMMS Failure

Computerized maintenance management systems (CMMS) and enterprise asset management (EAM) systems have been longtime fixtures in other industries, embraced to improve control over asset maintenance costs and improve asset performance. By Marcus McNeely, project manager, Blue Mountain Quality Resources, Inc.

Implementing A Supply Chain Risk Management Process

To paraphrase a television news show catch line, “It’s 10 p.m. Do you know where your product is?” Every life science executive has asked this question in one form or another. And, most of us have wondered about the answer. This becomes a much harder question to honestly answer as we grow our supply and fulfillment organizations over multiple countries in our quest to control c...

Guardrails Keep Oncology Waste Management on the Right Track

A large proportion of medical waste in oncology is considered hazardous and must be disposed of correctly. 

Friday 15th November 2019

QIAGEN Receives Several Conditional, Non-binding Indications of Interest, and Decides to Enter Into Discussions to Explore Potential Strategic Alternatives

Ad-hoc Announcement pursuant to Article 17 Market Abuse Regulation QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) ("QIAGEN" or the "Company") announces it has begun a review of potential strategic alternatives after receiving several conditional, non-binding indications of interest for the acquisition of all issued and outstanding shares of the Company. The Supervisory Board and the M...

Aimmune to Participate in Three Upcoming Investor Conferences

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the Aimmune executive management team will participate in three upcoming investor conferences in November and December: Event: Stifel 2019 Healthcare Conference Date: Wednesday, November 20, 2019 Presentation Time: 3:00 p.m. Eastern T...

University of California, Los Angeles Wins the Humana-Mays Health Care Analytics Case Competition

The student team of Ozguk Cetinok, Leah Kelly, and Erica Millwater from the University of California, Los Angeles (UCLA) has won the $30,000 First Place prize in the Humana-Mays Health Care Analytics 2019 Case Competition sponsored by health and well-being company Humana Inc. (NYSE: HUM) and Mays Business School at Texas A&M University.

QIAGEN Receives Several Conditional, Non-binding Indications of Interest, Enters Into Discussions to Explore Potential Strategic Alternatives

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) (“QIAGEN” or the “Company”) announces it has begun a review of potential strategic alternatives after receiving several conditional, non-binding indications of interest for the acquisition of all issued and outstanding shares of the Company. The Supervisory Board and the Management Board of QIAGEN, in accordance with their fiduciar...

Abacus Health Products Announces Release Date, Conference Call Details for 2019 Third Quarter Financial Results

Abacus Health Products, Inc. (CSE: ABCS, OTCQX: ABAHF) (“Abacus” or the “Company”) will release its 2019 third quarter financial results on Thursday, November 21, 2019, prior to the market open and management will host a conference call at 10:00 AM Eastern Time to review the financial results. Conference Call & Live Audio Webcast Details: All interested parties can join the confer...

Quantzig Helped a Canadian Pharmaceutical Company Improve Their Inventory Management Capability | Request a FREE Demo for In-depth Insights

Quantzig, a global data analytics and advisory firm, that delivers actionable analytics solutions to resolve complex business problems has announced the completion of its latest success story titled – ‘How Important is Inventory Management for Canad

Amgen and The Duke Clinical Research Institute Initiate First Large-Scale Registry to Evaluate Real-World Lipid Management and the Effectiveness of PCSK9 Inhibitors

THOUSAND OAKS, Calif., Nov. 15, 2019 /PRNewswire/ — Amgen (NASDAQ:AMGN) in collaboration with the Duke Clinical Research Institute (DCRI) today announced plans to initiate the Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 inhibitors (cvMOBIUS) study—the first large-scale real-world study to assess lipid management and the impact of PCSK9 inhibi...

Alliant Health Solutions Selected as Recipient of QIN-QIO Task Order 1 Award Under the 12th Statement of Work

On November 8, 2019, the Centers for Medicare & Medicaid Services (CMS) awarded a five-year contract to Alliant Health Solutions (AHS) to serve as a Quality Innovation Network – Quality Improvement Organization (QIN-QIO) under the recently launched 12th Statement of Work. QIN-QIOs serving under the 12th Statement of Work will provide targeted assistance to nursing homes and communities in...

Alpha Holdings Provides Update on Opposition to OncoSec Takeover Proposal

Lawsuits Against OncoSec Proceeding in Nevada District Court Remains Opposed to China Grand Transaction and Intends to Solicit Proxies from Shareholders at Special Meeting Alpha Holdings, Inc. (KOSDAQ: 117670) (“Alpha Holdings”), the largest stockholder of OncoSec Medical Incorporated (NASDAQ: ONCS) (“OncoSec” or the “Company”), with an approximate 15.1% ownership stake, today pro...

X4 Pharmaceuticals to Present at Stifel 2019 Healthcare Conference

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced that management will present at the Stifel 2019 Healthcare Conference on Tuesday, November 19th, 2019 at 8:35 am EST in New York, NY. About X4 Pharmaceuticals X4 Pharmaceuticals is developing novel therapeutics...

Anika Therapeutics Announces Participation in MEDICA International Trade Fair and International Cartilage Regeneration and Joint Preservation Society Focus Meeting

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid (HA) technology platf

The Boston Globe Names Beam Therapeutics a Top Place to Work For 2019

Magazine honors the best employers in Massachusetts Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, has been named one of the Top Places to Work in Massachusetts in the 12th annual employee-based survey project from The Boston Globe. Top Places to Work recognizes the most admired workplaces in the state voted on by the people who know them...

Oragenics, Inc. Publishes Peer-Reviewed Study in Journal of Peptide Science Demonstrating First Complete Chemical Synthesis of Bicyclic Ring of a Mutacin 1140 Analog

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announces the publication of the outcome of the a specific chemical synthesis of the bicyclic C/D ring of an analog of the company’s lantibiotic compound, Mutacin 1140. The study, titled “Complete synthesis of the bicyc...

Hancock Jaffe Enrolls and Successfully Implants Tenth VenoValve Patient

Initial Implantation Phase for First-in-Man Study Now Completed IRVINE, CA / ACCESSWIRE / November 15, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that it has enrolled and successfully implanted the 10th patient to complete the initial implantation phase of the first-in-man VenoValve...

BIONIK Laboratories Announces Second Quarter Fiscal 2020 Financial Results

BIONIK Laboratories Corp. (OTCQB: BNKL) ("BIONIK" or the "Company"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial results for the second quarter of fiscal year 2020, ended September 30, 2019. Financial information for the second quarter of fiscal...

Special Report From the SABM: The Choosing Wisely Campaign

Find out which Choosing Wisely recommendations have been set forth by the Society for the Advancement of Blood Management. Anesthesia & Analgesia

Samsung Biologics Achieves ISO27001 Certification

Becomes first CDMO to receive highly touted recognition for information security management.

Global ITasaService Market Size study, by Type Technical Infrastructure Architecture, IT Management Framework, Application Management, by Application BFSI, Telecom, Retail, Healthcare, Energy Utilities and Regional Forecasts 20182025 [Report Updated: 0

Global ITasaService Market valued approximately USD XX billion in 2017 is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 20182025. The ITasaService Market is continuously growing in the global scenario at significant pace. IT as a service ITaaS is an operational model where the information technology IT service provider delivers an information technology ...

CarePort Guide Joins Epic App Orchard Marketplace to Optimized Discharge Planning

– CarePort Health announced that CarePort Guide, its post-acute provider database and patient choice application, is now available in the Epic App Orchard marketplace. – The integration allows Epic customers to increase conversions to preferred providers while preserving patient choice. CarePort Health, a provider of care coordination and post-acute outcomes management announced that C...

Thursday 14th November 2019

[Articles] Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

The addition of isatuximab to pomalidomide–dexamethasone significantly improves progression-free survival in patients with relapsed and refractory multiple myeloma. Isatuximab is an important new treatment option for the management of relapsed and refractory myeloma, particularly for patients who become refractory to lenalidomide and a proteasome inhibitor.

Titan Medical Reports Third Quarter 2019 Financial Results

Titan Medical Inc. (TSX: TMD) (Nasdaq: TMDI) (“Titan” or “the Company”), a medical device company focused on the design and development of a single-port robotic surgical system for application in minimally invasive surgery (“MIS”), announces financial results for the three and nine months ended September 30, 2019. All financial results are prepared in accordance with International F...

Quick Search

News Quicklinks